Evidence map›Paper›PMID 38505422›Full record

ArticleFrontiers in pharmacology2024

Corrigendum:

Dinglan Wu, Zhu Wang, Muqi Lin, Yi Shang, Fei Wang, JiaYi Zhou, Fei Wang, Xiantong Zhang, Xiaomin Luo, Weiren Huang

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Erratum for
    2019
5 · Who and what money

Authors and funding

10 authors.

Dinglan Wu *Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Zhu Wang *Department of Urology, People's Hospital of Longhua Shenzhen, Southern Medical University, Shenzhen, China.
Muqi Lin *School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China.
Yi ShangAgricultural Genome Institute at Shenzhen, Chinese Academy of Agricultural Science, Shenzhen, China.
Fei WangDepartment of Urology, The Hospital of Hainan Province, Haikou, China.
JiaYi ZhouShenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Fei WangShenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Xiantong ZhangShenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Xiaomin LuoShenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Weiren HuangDepartment of Urology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, International Cancer Center, Shenzhen University School of Medicine, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2019.01287.].

Indexed as

Akt pathwayanti-cancerapoptosiscucurbitacin Cgrowth arrestnatural product

Identifiers

PMID38505422
PMCPMC10950444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.